6.
Heinolainen K, Karaman S, DAmico G, Tammela T, Sormunen R, Eklund L
. VEGFR3 Modulates Vascular Permeability by Controlling VEGF/VEGFR2 Signaling. Circ Res. 2017; 120(9):1414-1425.
PMC: 6959003.
DOI: 10.1161/CIRCRESAHA.116.310477.
View
7.
Dang Y, Lou J, Yan Y, Yu Y, Chen M, Sun G
. The role of the neutrophil Fcγ receptor I (CD64) index in diagnosing spontaneous bacterial peritonitis in cirrhotic patients. Int J Infect Dis. 2016; 49:154-60.
DOI: 10.1016/j.ijid.2016.06.021.
View
8.
Sun L, Yang X, Yuan Z, Wang H
. Metabolic Reprogramming in Immune Response and Tissue Inflammation. Arterioscler Thromb Vasc Biol. 2020; 40(9):1990-2001.
PMC: 7484156.
DOI: 10.1161/ATVBAHA.120.314037.
View
9.
Vich Vila A, Hu S, Andreu-Sanchez S, Collij V, Jansen B, Augustijn H
. Faecal metabolome and its determinants in inflammatory bowel disease. Gut. 2023; 72(8):1472-1485.
PMC: 10359577.
DOI: 10.1136/gutjnl-2022-328048.
View
10.
Biggins S, Angeli P, Garcia-Tsao G, Gines P, Ling S, Nadim M
. Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2021; 74(2):1014-1048.
DOI: 10.1002/hep.31884.
View
11.
Haussinger D, Dhiman R, Felipo V, Gorg B, Jalan R, Kircheis G
. Hepatic encephalopathy. Nat Rev Dis Primers. 2022; 8(1):43.
DOI: 10.1038/s41572-022-00366-6.
View
12.
Pallett L, Swadling L, Diniz M, Maini A, Schwabenland M, Dalmau Gasull A
. Tissue CD14CD8 T cells reprogrammed by myeloid cells and modulated by LPS. Nature. 2023; 614(7947):334-342.
DOI: 10.1038/s41586-022-05645-6.
View
13.
Yang Y, Liu R, Lee P, Yeh Y, Huang Y, Lee W
. Anti-VEGFR agents ameliorate hepatic venous dysregulation/microcirculatory dysfunction, splanchnic venous pooling and ascites of NASH-cirrhotic rat. Liver Int. 2013; 34(4):521-34.
DOI: 10.1111/liv.12299.
View
14.
Zardi E, Zardi D, Giorgi C, Chin D, Dobrina A
. Portopulmonary hypertension and hepatorenal syndrome. Two faces of the same coin. Eur J Intern Med. 2017; 43:22-27.
DOI: 10.1016/j.ejim.2017.05.028.
View
15.
Alvares-da-Silva M, Oliveira C, Fagan A, Longo L, Thoen R, Yoshimura Zitelli P
. Interaction of Microbiome, Diet, and Hospitalizations Between Brazilian and American Patients With Cirrhosis. Clin Gastroenterol Hepatol. 2021; 20(4):930-940.
PMC: 8486893.
DOI: 10.1016/j.cgh.2021.03.045.
View
16.
Fernandez M
. Molecular pathophysiology of portal hypertension. Hepatology. 2014; 61(4):1406-15.
DOI: 10.1002/hep.27343.
View
17.
Abraldes J, Rodriguez-Vilarrupla A, Graupera M, Zafra C, Garcia-Caldero H, Garcia-Pagan J
. Simvastatin treatment improves liver sinusoidal endothelial dysfunction in CCl4 cirrhotic rats. J Hepatol. 2007; 46(6):1040-6.
DOI: 10.1016/j.jhep.2007.01.020.
View
18.
Lehmann J, Praktiknjo M, Nielsen M, Schierwagen R, Meyer C, Thomas D
. Collagen type IV remodelling gender-specifically predicts mortality in decompensated cirrhosis. Liver Int. 2019; 39(5):885-893.
PMC: 6594031.
DOI: 10.1111/liv.14070.
View
19.
Meng X, Nikolic-Paterson D, Lan H
. TGF-β: the master regulator of fibrosis. Nat Rev Nephrol. 2016; 12(6):325-38.
DOI: 10.1038/nrneph.2016.48.
View
20.
Alukal J, John S, Thuluvath P
. Hyponatremia in Cirrhosis: An Update. Am J Gastroenterol. 2020; 115(11):1775-1785.
DOI: 10.14309/ajg.0000000000000786.
View